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The importance of viral agents in the development of cutaneous T-cell lymphomas (CTCL) is still debated. For
this purpose, we retrospectively evaluated the EpsteinBarr virus (EBV) presence in Se´zary syndrome (SS),
mycosis fungoides (MF), inflammatory dermatoses (ID), and healthy donors (HD) using different approaches:
EBV-DNA was quantified in skin biopsies and peripheral blood using real-time PCR, EBV-encoded small RNA
(EBER) transcripts were detected by in situ hybridization (ISH), and latent membrane protein1-2 antigens were
detected by immunohistochemistry. Skin biopsies were EBV-DNA-positive in 8/30 (27%) SS, 7/71 (10%) MF, and 2/
18 (11%) ID patients and in none of the 25 normal skin samples. Positive mRNA (EBER) signals, always confined
to cerebriform T lymphocytes, were found in 5/30 SS patients (17%), whereas signals in all MF and ID patients
were negative. The presence of EBV-DNA in skin and blood samples was associated with a significantly lower
survival in MF/SS patients. In evaluating EBV serological status, most (470%) SS, MF, and ID patients showed a
serological reactivation demonstrated by the presence of anti-EA IgG. In conclusion, although the finding of
EBV-DNA in CTCL does not prove its etiopathogenetic role and may be related instead to immunosuppression,
our study demonstrates that it has prognostic relevance.
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INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) are a hetero-
geneous group of extranodal, non-Hodgkin’s lymphomas
characterized by a primary localization of atypical T
lymphocytes into the skin. Mycosis fungoides (MF), the most
common form of CTCL, originates from a clonal expansion of
epidermotropic CD4þ memory T cells (Siegel et al., 2000)
and is characterized by an indolent disease course and a
stepwise evolution with sequential appearance of patches,
plaques, and tumors. Se´zary syndrome (SS), included among
the aggressive cutaneous lymphomas in the new World
Health OrganizationEuropean Organization of Research
and Treatment of Cancer classification (Willemze et al.,
2005), is a rare, primary epidermotropic CTCL characterized
by erythroderma, peripheral adenopathies, and blood in-
volvement by atypical lymphocytes with cerebriform nuclei.
The etiopathogenesis of MF and SS remains obscure
despite several investigations. Infectious, environmental, and
genetic factors have been implicated as potential etiological
agents (Zucker-Franklin and Pancake, 1994). It has been
suggested that antigenic stimulation could be provoked by
persistent infectious agents such as the human T-cell
leukemia virus and the EpsteinBarr virus (EBV; Manca
et al., 1994; Pancake et al., 1995; Anagnostopoulos et al.,
1996; Shimakage et al., 2001). EBV is a herpesvirus with a
worldwide distribution; it is strongly associated with various
lymphoproliferative diseases, including Burkitt’s lymphoma,
posttransplantation lymphoproliferative disorders, Hodgkin’s
lymphoma, nasal T-cell lymphoma, and some peripheral T-
cell lymphomas (Anagnostopoulos et al., 1989; Zhou et al.,
2007) or nasopharyngeal carcinoma (Burgos, 2005).
Conflicting results, with an incidence ranging between 0
and 100% (Su et al., 1993; Iwatsuki et al., 1997; Shimakage
et al., 2001), emerge from studies investigating the role of
EBV in CTCL; such studies are limited by the small number of
subjects examined. Moreover, the different sensitivities of the
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technical methods used to evaluate the presence of viral
DNA or virus-related antigens (immunohistochemistry (IHC),
in situ hybridization (ISH), PCR), make it impossible to
compare the results (Erkek et al., 2001). A relationship
between EBV and rapid clinical progression has been
suggested both in MF (Mouly et al., 1996) and in SS (Foulc
et al., 2003).
The aim of this study was to investigate the role of EBV and
its prognostic value in CTCL. For this purpose, we retro-
spectively evaluated the presence of EBV in a large cohort of
SS and MF patients, in inflammatory dermatoses (ID) patients,
and in healthy donors (HD) using different approaches.
RESULTS
EBV-DNA quantification in skin and blood
Skin biopsies were EBV-DNA-positive in 8/30 (27%) SS and
only 7/71 (10%) MF samples (P¼0.03); the median EBV-
DNA load was significantly higher (Po0.0001) in SS (2,160
copies per mg, range 10–81,723) than in MF patients (122
copies per mg, range 42–505; Table 1). EBV-DNA was found
in 2/18 (11%) ID patients with a very low viral load (63 and
90 copies, respectively) and in none of the 25 skin samples
from healthy control subjects of the Turin Skin Bank (Table 1).
In 15/30 SS, 35/71 MF, and 8/18 ID patients, EBV presence
was also evaluated using EBV-encoded small RNA (EBER) in
situ hybridization and anti-latent membrane protein (LMP)1-2
antibodies in IHC. Positive mRNA (EBER) signals were found
in five SS patients (17%), all previously positive for EBV-
DNA, whereas the signals of all MF and ID patients were
negative. In all five cases, the positivity was confined to T
CD3þ lymphocytes, as demonstrated by double staining
(Figure 1a and b) and was never found in keratinocytes
(Figure 1c). Positivity was not observed with anti-LMP1-2
antibodies in any cases (data not shown).
Also in the blood, the highest percentage of EBV-DNA-
positive peripheral blood mononuclear cells (PBMC) samples
was found in SS patients (9/25, 36%), even if the difference
with respect to MF (7/27, 26%) and ID (4/18, 22.2%) was less
evident (Table 1). The concordance between skin and blood
positivity was documented in a minority of samples (12% in
SS, 11% in MF, 10% in ID; Table 1). No EBV-DNA positivity
was seen in blood samples from HD. The median PBMC viral
load was lower than in the skin, but again higher in SS than in
MF (median: 50 vs 13.5 copies per mg). The highest values
(137,000 and 1,904, respectively) were found in two patients
with EBV reactivation serologically demonstrated by the
presence of anti-EA-IgG antibodies.
The availability of serial samples in a proportion of our
patients allowed us to document, both in blood (2/3 patients)
and in skin (1/11 patients), the appearance of EBV-DNA
positivity during follow-up.
Factors associated with EBV-DNA presence and relation to
disease course
No differences were found in SS between EBV-positive and -
negative samples according to gender, median age, and
number of circulating Se´zary cells. On the other hand, the
finding of a cutaneous EBV-DNA positivity in MF increased
with disease progression (Table 2) and the highest prevalence
was observed in transformed MF (3/6 patients, or 50% of
cases). In PBMC from MF, EBV-DNA positivity was more
frequently found in patients who had a clonal TCR
Table 1. EBV-DNA (EBNA-1) positivity in skin and
blood samples
Skin Blood Skin and blood
SS 8/30 (27%) 9/25 (36%) 3/25 (12%)
range 10–81,723 range 10-137,000
MF 7/71 (10%) 7/27 (26%) 3/27 (11%)
range 42–505 range 10–1,904
ID 2/18 (11%) 4/18 (22%) 1 (10%) (n=10)
range 63–90 range 66–7,143
HD 0/25 0/20 —
HD, healthy donors; ID, inflammatory dermatoses; MF, mycosis
fungoides; SS, Se´zary syndrome.
Figure 1. ISH EBER localization in SS skin infiltrating lymphocytes. (a) ISH EBER-positive lymphocytes in an SS patient; the inset shows an atypical EBER-
positive cerebriform lymphocyte. (b) Double staining: ISH EBER (brown nuclei) and CD3 (red/purple membrane and cytoplasm) showing the T nature of EBER-
positive lymphocytes in the same patient. (c) A single EBER-positive lymphocyte among negative keratinocytes. Scale bar¼ 20 mm.







I (n=49) 2 (4.11–2.8%2) 10–360
II (n=16) 4 (251–5.6%2) 42–505
III (n=3) 1 (331–1.4%2) 123
IV (n=3) 0% 0
Total (n=71) 7 (9.9%2)
MF, mycosis fungoides.
1Percentage of patients at the stage.
2Percentage of total MF patients.
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rearrangement (50% positivity in monoclonal cases com-
pared with 26% in polyclonal cases).
No differences in CD19þ , CD3þCD8þ , CD8þHLADRþ ,
CD3-CD16/CD56þ (natural killer), CD3þCD57þ ,
CD8þCD28þ , or TCR-g/d subset expression were found
between EBV-positive and EBV-negative patients in SS, MF,
and HD. As expected, the median values of all these markers
were lower in SS than in MF or ID because of the presence of
an increased CD4þ atypical population (Table S1).
The EBV-DNA presence in the skin was evaluated in a
univariate analysis according to the disease course: MF and SS
survival was significantly higher in EBV-DNA-negative (med-
ian: undefined and 3.13 years, respectively) vs EBV-DNA-
positive (median: 2.94 and 1.31 years, respectively) patients
(Figure 2). Similar results were observed when detecting EBV-
EBER mRNA in SS, although the number of patients analyzed
was small (median survival: 7.01 vs 0.74 years, respectively.
Figure S1). With regard to PBMC, the survival of both MF and
SS was also significantly higher in EBV-DNA-negative (median:
13.12 and 5.13 years, respectively) vs EBV-DNA-positive
(median: 3.41 and 1.71 years, respectively) patients (Figure 2).
In evaluating EBV serological status, most SS (96%) and
MF patients (97%) showed a past EBV infection (anti-VCA
IgG seropositive and anti-VCA IgM seronegative, anti-EBNA1
IgG seropositive). Similar data were seen in ID (100%) and
HD (94%). Anti-VCA IgG values were higher in SS (median
172.2, range: 0–1809.5) and MF patients (median: 160.8,
range: 0–1969) than in ID (median: 91.35, range: 8.8–1955)
and HD (median: 84.0 range: 0–207). A statistically
significant difference was seen only between SS and MF vs
HD (Po0.05 and 0.01, respectively). EBV serological
evidence of reactivation, demonstrated by the finding of
anti-EA IgG antibodies, was seen in SS, MF, and ID (80, 75,
and 71%, respectively), whereas in HD the percentage was
lower (28%). Serological evidence of reactivation and EBV-
DNA load were not correlated, because high anti-EA IgG
antibodies were found in 75% of EBV-DNA-negative vs 79%
of EBV-DNA-positive patients.
DISCUSSION
After primary infection, EBV establishes life-long and predomi-
nantly latent infection of B cells. In a minority of infected
subjects, EBV is linked with the development of lympho-
and epithelioproliferative disorders. In iatrogenically or
naturally immunosuppressed hosts, EBV is a major risk for
the development of lymphoproliferative disorders (Stevens et al.,
2002).
Despite the wide variety of assays, specimens, and patient
populations studied, overall consensus exists that trans-
planted patients with or without posttransplantation lympho-
proliferative disorders and HIV-infected patients have a
significantly higher EBV burden in peripheral blood com-
pared with healthy EBV-seropositive donors (Dehee et al.,
2001; Stevens et al., 2002; Fafi-Kremer et al., 2004; Fellner
et al., 2007). The elevation of EBV load in the circulation
seems to reflect aberrant EBV-induced B-cell proliferation in
(pre-)posttransplantation lymphoproliferative disorder tissue
and impaired anti-EBV T-cell immunosurveillance.
Increasing evidence indicates that EBV may be able to infect
T lymphocytes (Dreno et al., 1993, 1994) and EBV-positive
T-cell lymphomas have been reported in Japan and Europe,
consisting mainly of hemophagocytic syndrome-associated
lymphoma, nasal T-cell lymphoma, and peripheral T-cell
lymphoma (Kim et al., 2006; Delecluse et al., 2007).
In this study we describe the prognostic relevance of EBV-
DNA presence in a large cohort of CTCL. In skin samples, we
found an EBV-DNA prevalence of 27% in SS, 10% in MF, and
11% in ID, whereas healthy control subjects were all
negative for EBV-DNA. We believe this is an important
finding, particularly when compared with the previously
reported presence of parvovirus- and HHV7-DNA in normal
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Figure 2. Survival (in years) of SS/MF patients according to the EBV status in skin and blood.
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The presence of EBV-DNA in skin and blood was
significantly correlated with survival both in SS and in MF
patients. To our knowledge, the prognostic relevance of EBV
presence in blood samples is previously unreported, whereas
our data confirm the unfavorable prognostic value of EBV
already observed by Foulc et al. (2003) in SS skin. These
authors reported mRNA Bam H-fragment, lower strand frame
detection by ISH in keratinocytes as a negative prognostic
factor in SS, whereas the presence of EBER mRNA was not
significantly correlated with survival. Our results agree with
data reported by Park and Ko (1996) showing EBER positivity
only in CD20 lymphocytes, whereas others authors (Dreno
et al., 1994; Shimakage et al., 2001; Foulc et al., 2003; Knol
et al., 2005) also found EBV-positive hybridization signals in
keratinocytes and in Langerhans cells. For this purpose, the
double staining of SS skin sections with EBER1-ISH and anti
CD3 allowed us to clarify that EBV infects selectively atypical
T lymphocytes, whereas keratinocytes and Langerhans cells
were always negative for EBV (Figure 1). Even if we cannot
exclude the usual EBV-DNA localization in peripheral blood B
lymphocytes, the very low level of B cells (o20 cells per mm3)
in our SS patients suggests its possible T-cell localization.
The discrepant results among PCR and ISH/IHC are
probably caused by the low number of infected cells in
tissue sections (as reported in the literature, all MF/SS cases
were constantly LMP-negative (Anagnostopoulos et al., 1996;
Iwatsuki et al., 1997).
So far, the finding of EBV-DNA in CTCL does not prove its
etiopathogenetic role and EBV positivity may be related to
immunosuppression rather than to the type of lymphoma. A
small percentage of good-prognosis CTCL were found to be
EBV-DNA-positive; on the contrary, the percentage of positive
cases increases in advanced-stage MF, in SS, and in systemic
CD30þ anaplastic large cell lymphoma of the adult (Kim et al.,
2006), in which immunodeficiency is more common.
The relative lymphopenia of non-neoplastic T cells in SS
may account for the compromised immunosurveillance with
frequent opportunistic infections. The causative role of EBV in
B-cell lymphomas has been demonstrated in previous studies
(van de Rijn et al., 1996) with double labeling by ISH and
IHC, in which the EBV genome was localized in malignant B
cells. Neoplastic B cells have been shown to contain clonal
immunoglobulin gene rearrangement and clonal EBV gen-
ome. To date, we have no data on the clonality of EBV but we
can emphasize a major difference represented by the
percentage of EBV-positive neoplastic cells in ISH: the
majority of large B-cell lymphoma cells (490%) show a
positive reaction compared with a minority (o10%) of CTCL
cells. The observation that only a few neoplastic cells are
infected by EBV in CTCL provides evidence against a
causative role. Our finding of EBV positivity in previously
negative skin and blood samples during follow-up seems to
support the immunosuppression hypothesis rather than an
etiopathogenetic role. On the other hand, our finding of EBV-
DNA absence in normal skin and the recently reported (Knol
et al., 2005) detection of EBV-specific CD8þ tumor infiltrat-
ing lymphocytes in SS support the hypothesis that EBV could
play a role in the development of CTCL.
As expected, serological data are less relevant: most
healthy and pathological subjects showed serological evi-
dence of a past infection (Jumbou et al. 1997) and no
correlation between serological evidence of EBV reactivation
and EBV-DNA load in peripheral blood (Ga¨rtner et al., 2000;
Merlino et al., 2003).
In conclusion, our results emphasize the clinical relevance
of EBV monitoring in CTCL patients. The presence of EBV-
DNA both in skin and in blood is an additional unfavorable
prognostic factor to add to those already known, such as age,
disease stage, and lactate dehydrogenase value. To better
assess the role of EBV in CTCLs, it is our intention to
prospectively investigate EBV latent and lytic gene expression
by employing a system of two multiplex-nested reverse-
transcription-PCRs that allow the detection of a pattern of
seven latent/immortalizing and lytic EBV transcripts. More-
over, because EBV has been shown to be exclusively related
to p16-deficient Burkitt’s lymphoma (Cerimele et al., 2005), it
could be intriguing to investigate whether EBV infects




This study was performed in compliance with the principles of good
clinical practice and according to the Declaration of Helsinki
Principles. The study protocol was approved by the Turin University
Ethical Committee. All patients were included after providing written
informed consent.
Skin biopsies and PBMC samples were obtained from 30 SS (15
women and 15 men; mean age¼ 68 years, median age¼ 70 years,
range 47–84), 71 MF patients (29 women and 45 men; mean
age¼ 61 years, median age¼ 62 years, range 13–84), and 18 ID (10
psoriasis, 4 atopic dermatitis/contact dermatitis, 4 pseudolymphoma
patients; 8 women and 10 men; mean age¼ 64 years, median age 67
years, range 33–79; 11/18 patients were erythrodermic). Skin
samples from 25 Piedmont Regional Skin Bank donors and blood
samples from 55 Turin Blood Bank donors were used as healthy
control subjects. All control subjects were age- and sex-matched.
The diagnosis of MF was made according to standard clinical and
immunopathological findings (Willemze et al., 2005); MF patients
were classified according to the new tumor, node, metastasis (TNM)
staging of the Mycosis Fungoides Cooperative Group, (Olsen et al.,
2007). MF patients were stratified according to TNM: 49 stage I, 16
stage II, 3 stage III, and 3 stage IV. Of the 71 MF patients, 6 (8%)
showed transformation into high-grade lymphoma during follow-up.
SS diagnostic criteria (Russell-Jones, 2005) included (1) erythro-
derma and peripheral lymphadenopathies; (2) peripheral blood
involvement by circulating Se´zary cells; and (3) cutaneous biopsy
proving CTCL, confirmed by the finding of a clonal TCR-g gene
rearrangement. Peripheral blood involvement was defined according
to the criteria recently proposed by the International Society for
Cutaneous Lymphoma (Vonderheid and Bernengo, 2003). All SS
patients showed an identical clone both in skin and in blood.
Peripheral blood involvement by Se´zary cells ranged from 18 to 98%
(median: 69%).
The biopsy specimen was divided into two pieces: one was
processed for histologic evaluation on paraffin-embedded sections
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and the other was cryopreserved for immunoistochemical staining
and TCR-g clonality studies and thereafter used for virological
analysis. Ficoll-isolated PBMC were used for TCR-g analysis flow-
cytometry immunophenotyping (Bernengo et al., 2001) and EBV-
DNA detection.
TCR-g gene rearrangement was studied by carrying out a multiplex
PCR/hetheroduplex analysis on PAGE in both skin specimens and
blood samples (Ponti et al., 2005) or by GeneScan capillary
electrophoresis analysis as described elsewere (Ponti et al., 2008a).
Immunohistochemistry
IHC on 5-mm cryostatic sections was performed in all cases using the
standard streptavidin–biotin–peroxidase method (LSAB2plus Kit; Dako,
Glostrup, Denmark) using a wide panel of monoclonal antibodies
directed against T-cell lineage, as well as activation and proliferation
antigens. Staining for EBV on paraffin-embedded tissue sections was
performed using the anti-LMP1-2 monoclonal antibody (clones CS.1,
CS.2, CS.3, and CS.4) provided by Dako Italia (Milan, Italy). EBV-
infected lymph node sections were used as positive controls.
Double staining: EBER ISH–CD3 IHC
In all five EBER-positive SS skin samples, we performed double
staining: the first step consisted of EBER ISH staining developed using
peroxidase and diaminobenzidine as chromogen, followed by MW
antigen retrieval in citrate buffer, pH 6, and anti-CD3 phosphata-
se–alkaline staining using new fuchsin as chromogen.
Flow cytometry
Peripheral blood lymphocytes were analyzed using a FACSCalibur
cytometer (Becton Dickinson, San Jose, CA). Three- or four-color
immunofluorescence analyses were performed simultaneously using
FITC-, PE-, PerCP-, and APC-conjugated antibodies as described
previously (Bernengo et al., 2001). A wide panel of mAbs directed
against B-, T-, and natural killer-cell antigens and TCR-b-chain
variable regions was routinely tested.
In situ hybridization
Slides were deparaffinized and rehydrated. After a treatment with
proteinase K, EBER were detected by complementary fluorescein-
labeled probes, followed by the application of an antifluorescein
antibody and a final incubation with diaminobenzidine solution to
stain positive cells. All materials (the Bond ISH system) were
provided by A. Menarini Diagnostics (Firenze, Italy). All cases with
at least one positive cell were considered EBER-positive. An EBV-
infected lymph node section was used as positive control.
EBV-DNA quantification by real-time PCR
Genomic DNA was extracted from 15 to 20 20-mmOCT-cryopreserved
tissue sections and from peripheral blood lymphocytes after centrifuga-
tion with Ficoll–Hypaque (Nycomed, Oslo, Norway) using a Qiagen
tissue kit (QIAamp DNA Mini Kit; Qiagen GmbH, Hilden, Germany),
according to the manufacturer’s instructions.
The measurement of viral load was performed with the Q-EBV
Real Time System (Amplimedical SpA; Diagnostic Group, Turin,
Italy), which uses primers and probes that recognize the EBV latency
gene for EBNA-1 antigen and the human gene for b-globin as
amplification internal control. The detection range was 1–10 copies
per mg or 1–10 copies per 105 PBMC.
EBV serology
IgG and IgM anti-VCA, IgG anti-EBNA1, and IgG anti-EA-D were
detected by ELISA using commercial kits according to the manufac-
turer’s instructions (BEIA EBV VCA IgG and IgM Quant and BEIA EBV
EBNA1 IgG Quant from Technogenetics, Milan, Italy, and Captia EBV
EA-D IgG from Trinity Biotech, Jamestown, NY, respectively). Values
are expressed in arbitrary units per ml (AUml1).
Statistical analysis
Statistical analyses were performed using Graph Pad Prism, version
3.00 for Windows (Graph Pad Software, San Diego, CA). Univariate
analysis was arranged with either an aw2 test or a t test when
appropriate. Data were expressed as the mean±standard deviation
and evaluated by analysis of variance, followed by the Bonferroni
post hoc test. Survival was established from CTCL diagnosis to the
date of death or last known date alive, counting all deaths as events.
Life-table estimates of survival were derived by the Kaplan–Meier
method and compared statistically using the stratified log-rank test of
Mantel.
In all but one case, the biopsy we analyzed was that performed at
diagnosis, whereas peripheral blood lymphocytes samples were in
part collected later on.
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